Evidence map›Paper›PMID 42183936›Full record

ArticleDiscover oncology2026

A literature-guided integrative transcriptomic analysis framework for prioritizing angiogenesis-associated genes across cancers.

Jingcan You, Liqun Wang, Yongjie Li

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jingcan YouBasic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education; Luzhou Municipal Key Laboratory of Thrombosis and Vascular Biology; Laboratory for Cardiovascular Pharmacology, Department of Pharmacology; School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Liqun WangBasic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education; Luzhou Municipal Key Laboratory of Thrombosis and Vascular Biology; Laboratory for Cardiovascular Pharmacology, Department of Pharmacology; School of Pharmacy, Southwest Medical University, Luzhou, 646000, China. liqunwang@swmu.edu.cn.
Yongjie LiBasic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education; Luzhou Municipal Key Laboratory of Thrombosis and Vascular Biology; Laboratory for Cardiovascular Pharmacology, Department of Pharmacology; School of Pharmacy, Southwest Medical University, Luzhou, 646000, China. liyongjie@swmu.edu.cn.

Funding

Science and Technology Agency of Sichuan Province 2015JY0092
6 · The paper itself

Abstract

Angiogenesis is a fundamental process in cancer progression, but computational prioritization of angiogenesis-associated genes often relies on predefined gene sets or canonical signaling pathways, limiting the identification of non-canonical and context-dependent regulatory programs. To address this limitation, we developed a literature-guided integrative transcriptomic framework to prioritize angiogenesis-associated candidates across heterogeneous cancer types. The framework integrates bibliometric trend profiling, pan-cancer gene expression analysis, survival association assessment, tumor microenvironment-related transcriptional characterization, and functional enrichment analysis. Rather than prespecifying angiogenic regulators, candidate genes were prioritized through convergence across these complementary evidence layers. Across diverse cancer cohorts, the framework consistently identified cadherin 2 (CDH2) as a representative non-canonical angiogenesis-associated signal. CDH2-associated transcriptional programs were enriched in extracellular matrix organization, cell-cell adhesion, and structural remodeling processes, and tumor microenvironment analyses indicated preferential alignment with stromal and vascular-associated features, particularly cancer-associated fibroblast-related signatures, rather than immune-dominant profiles. In independent external glioma cohorts, CDH2 showed a non-uniform and context-dependent relationship with vascular endothelial growth factor A (VEGFA)-associated transcriptional patterns, while CDH2-high tumors reproducibly exhibited higher extracellular matrix remodeling, adhesion/focal adhesion, epithelial-mesenchymal transition, and angiogenesis-related signature scores. In an independent Chinese Glioma Genome Atlas cohort, higher CDH2 expression was also associated with worse overall survival in a lower-grade glioma-preferred subset. Collectively, this study demonstrates the utility of a knowledge-guided integrative transcriptomic framework for prioritizing angiogenesis-associated genes beyond canonical regulators and highlights structure-oriented, non-canonical angiogenesis-related programs as reproducible biological signals.

Indexed as

AngiogenesisGene prioritizationIntegrative transcriptomicsKnowledge-guided analysisPan-cancer analysisTumor microenvironment

Identifiers

PMID42183936
PMCPMC13385324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.